Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo-CPAP Clear all
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 2, 2026, 6:32 AM EDT
Not listed Phase 4 Interventional

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

NCT02140580
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Minimally invasive surfactant therapy, Continuation on CPAP
Device · Other
Lead sponsor
Menzies Institute for Medical Research
Other
Eligibility
1 Minute to 6 Hours
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 2, 2026, 6:32 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment

NCT07210606
View directory record Official record
Conditions
Sleep Disordered Breathing, Able Bodied
Interventions
Trazodone + PAP therapy, Oxygen + PAP therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Not applicable Interventional

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

NCT03312556
View directory record Official record
Conditions
Supine Hypertension, Autonomic Failure
Interventions
continuous positive airway pressure (CPAP), Placebo
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ezopiclone Improves the Quality of Overnight Polysomnography

NCT00507117
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Lunesta, Placebo control
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 4 Interventional

Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

NCT00612157
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo control
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107809
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional

Endothelial Function in Obstructive Sleep Apnea

NCT03122639
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult
Interventions
Atorvastatin 10mg, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Effects of Treating Obstructive Sleep Apnea in Epilepsy

NCT00047463
View directory record Official record
Conditions
Epilepsy, Sleep Apnea, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), Placebo-CPAP
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
4
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome

NCT01768065
View directory record Official record
Conditions
Organic Pediatric Obstructive Sleep Apnea
Interventions
Nasal Expiratory Positive Airway Pressure Device, placebo sham
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 16 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema

NCT04186598
View directory record Official record
Conditions
Continuous Positive Airway Pressure, High Altitude Pulmonary Edema
Interventions
CPAP mask system, Nifedipine 30 MG, CPAP mask system without PEEP
Device · Drug
Lead sponsor
CommonSpirit Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Breckenridge, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

NCT05951023
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone 2 mg, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Not applicable Interventional Results available

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

NCT01196117
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
14 days of placebo therapy, 14 days of CPAP therapy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Results available

Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?

NCT05094271
View directory record Official record
Conditions
OSA, Sleep Apnea, Obstructive Sleep Apnea, Alzheimer Disease
Interventions
Supplemental Oxygen, Continuous Positive Airway Pressure Machine, Room Air
Other · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
65 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Not applicable Interventional Results available

NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy

NCT02107300
View directory record Official record
Conditions
Xerostomia
Interventions
NeutraSal, Placebo Comparator
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 2, 2026, 6:32 AM EDT
Terminated Phase 4 Interventional Results available

Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea

NCT00730041
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Pillar Palatal Implant System, Sham system
Device
Lead sponsor
Medtronic Xomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • Berkeley, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Sep 2, 2026, 6:32 AM EDT
Recruiting Phase 3 Interventional

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

NCT05960929
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Interventions
Infasurf Aero™
Combination Product
Lead sponsor
ONY
Industry
Eligibility
29 Weeks to 36 Weeks
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 3 Interventional

Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

NCT00665977
View directory record Official record
Conditions
Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
Interventions
Thermosmart & placebo, Placebo Device & Nasacort, Placebo Arm
Drug · Device
Lead sponsor
Clayton Sleep Insititute
Industry
Eligibility
16 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 6, 2010 · Synced Sep 2, 2026, 6:32 AM EDT
Withdrawn Not applicable Interventional

Reproductive Aging and Obstructive Sleep Apnea

NCT01850992
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Active CPAP, Sham CPAP
Device
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 70 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

NCT04639193
View directory record Official record
Conditions
OSA, Obstructive Sleep Apnea
Interventions
Acetazolamide, Eszopiclone, Placebo, Venlafaxine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 2, 2026, 6:32 AM EDT
Withdrawn Phase 4 Interventional

Ramelteon for Complex Insomnia in Veterans With PTSD

NCT03265951
View directory record Official record
Conditions
Insomnia
Interventions
Ramelteon, Usual Care
Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 2, 2026, 6:32 AM EDT
Completed Not applicable Interventional Results available

Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome

NCT01808508
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea Syndrome
Interventions
Continuous positive airway pressure, Sham or placebo continuous positive airway pressure
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 20 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 2, 2026, 6:32 AM EDT